Serum gamma-glutamyl transferase activity: a new marker for stent restenosis?
Stent restenosis remains the main limitation of percutaneous coronary intervention. Elevated serum gamma-glutamyl transferase (GGT) level is associated with an inflammatory response. We aimed to determine the correlation of stent restenosis with the serums level of GGT. One hundred and twenty patients (age 58.56+/-10.46 years, 66% male) with a history of coronary stent implantation and had undergone control coronary angiography (60 with restenosis and 60 without) were included. All had baseline serum GGT activity and were free of systemic and hepatobiliary disease. Median baseline serum GGT activity was significantly higher in patients with restenosis (34.00 U/L (24.00-47.75)) than in those without restenosis (21.00 U/L (17.25-26.7500)) (P<0.0001). Stent restenosis was identified in 38% of the patients with a serum GGT value >40 U/L and in 5% of patients with a serum GGT value <or=40 U/L (P<0.001). Serum C-reactive protein (CRP) and total bilirubin levels were significantly higher (P=0.011 and 0.037, respectively) and alkaline phosphatase levels were significantly lower in patients with restenosis (P=0.029). Levels of GGT, CRP, and alkaline phosphatase were independent predictors of restenosis (P=0.001, 0.019 and 0.004, respectively). In conclusion, the serum level of GGT may be an independent marker for stent restenosis.